Objective: Multidrug resistance is a major problem of Pseudomonas aeruginosa strains. We aimed to determine the level of resistance to the antipseudomonal antibiotics, the change in the rates of antibiotic resistance over the years, and mortality rate during hospital stay.
INTRODUCTION
Pseudomonas aeruginosa is a bacterium that easily colonizes in the hospital environment. Thus, it causes nosocomial infections. This bacterium, which is an important opportunistic pathogen, is responsible for 10%-15% of nosocomial infections worldwide, and it is ranked as the 5 th most common nosocomial infection (1, 2) .
Multidrug resistance (MDR) is a major problem of P. aeruginosa strains. The development of MDR during treatment creates difficulties in the treatment of the infection (2) . MDR is defined as Pseudomonas infection that is resistant to at least three antibiotics from the groups of β-lactam, carbapenem, aminoglycoside, and fluoroquinolone (3) . In hospital-acquired pseudomonal pneumonia, mortality was reported to be around 70% in some studies (4) .
This study aimed to determine the antibiotic resistance rates of P. aeruginosa strains isolated from sputum and bronchial lavage samples that were sent to the microbiology laboratory of Chest Diseases Hospital between January 2009 and December 2013, the distribution of these rates over the years, and the mortality rate during hospitalization of patients with Pseudomonas infection.
METHODS
In this study, 505 P. aeruginosa strains isolated from 485 bronchial lavage and 3708 sputum samples that were sent to the microbiology laboratory for culture antibiogram between January 1, 2009 Strains were defined using conventional diagnostic methods and Api 20 NE (Bio-Merieux, France) system. Antibiotic susceptibility was investigated through the Kirby-Bauer disc diffusion method using Mueller-Hinton agar in accordance with the criteria of "Clinical and Laboratory Standards Institute" (CLSI) (5) . Susceptibilities to imipenem (IMP), amikacin (AK), tobramycin (TOB), ciprofloxacin (CIP), piperacillin (PIP), PIP/tazobactam (P/T), ceftazidime (CAZ), and cefepime (FEP) were evaluated in the isolated strains. The mortality rates during hospitalization were detected for patients with P. aeruginosa. While calculating the rates of antibiotic susceptibility, moderately susceptible strains were also accepted as resistant. Pseudomonas strains were defined as resistant in the presence of resistance to at least one of the anti-pseudomonas antibiotics and as multidrug resistant (MDR) in the presence of resistance to three or more drugs from the groups of β-lactam, carbapenem, aminoglycoside, and fluoroquinolone antibiotics.
Statistical Analysis
In the study, Chi-square analysis was used for evaluating the differences between the rates of resistant strains in 2009 and 2013 for eight different antibiotics. The results were evaluated by considering 95% confidence level.
RESULTS
P. aeruginosa strains were found in 505 patients admitted between 2009 and 2013. Of these patients, 401 (79.4%) were male and 104 (20.6%) were female. The mean age of patients was 65±12.4 years. P. aeruginosa was isolated from sputum in 477 cases (94.5%) and from bronchial lavage in 28 cases (5.5%). Although the number of patients with P. aeruginosa was 44 in 2009, it increased up to 185 in 2013 (Table 1).
With respect to the diagnoses of diseases, P. aeruginosa was reproduced in chronic obstructive pulmonary disease, bronchiectasis, and bronchogenic carcinoma more frequently ( Table 2 ).
The study revealed that the antibiotics to which P. aeruginosa strains were mostly resistant were FEP (26.7%) and CAZ (23.2%). On the other hand, the lowest resistance rates were AK (7.3%) and TOB (11.9%) (while calculating the resistance rates, moderately susceptible strains were also accepted to be resistant) ( Table 3 ).
The distributions of the rates of resistance to anti-pseudomonal antibiotics over the years are shown in Table 4 . In the evaluation of differences between resistant strains in 2009 and 2013 through chisquare analysis, no statistically significant difference was observed between resistance rates in 2009 and 2013 for IMP, TOB, PIP, P/T, and CAZ antibiotics (p>0.05). On the other hand, there was a statistically significant difference for the CIP, AK, and FEP antibiotics (p<0.01). The resistance rates for CIP, AK, and FEP were found to be significantly higher in 2009 than those in 2013. In other words, a decline was observed in the resistance rates of CIP, AK, and FEP over the years. In our study, although no antibiotic resistance was detected in 53.5% of P. aeruginosa strains, 23.6% displayed resistance to three or more antibiotics (Table 5) .
Although the rate of P. aeruginosa strain resistance to only one antibiotic group from β-lactam, carbapenem, aminoglycoside, and fluoroquinolone was 19.2%, the rate of P. aeruginosa strain resistance to all of these four antibiotic groups was 4% (Table 6 ).
It was observed that the MDR strain rate, which was 18.2% in 2009, decreased to 12.4% in 2013 ( Table 7 ).
The mortality rate that developed during hospital stay in P. aeruginosa-isolated patients was found to be 6.7% (34 patients).
DISCUSSION
P. aeruginosa is a gram-negative, aerobic rod-shaped bacterium belonging to the family Pseudomonadaceae.
In P. aeruginosa strains, MDR is an important issue, and only a few antibiotics were found to be effective against P. aeruginosa (6). The bacterium has a resistance mechanism combined with a low intrinsic outer membrane permeability, formation of cephalosporinase, and presence of an efflux pump. As a result, when MDR Pseudomonas infections occur with wrong drug use, they create serious problems in nosocomial infections (7) .
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The definition of MDR Pseudomonas infection differs. Although resistance to a single antibiotic group is defined as MDR in some studies, resistance to all tested antibiotics is accepted as MDR in other studies (8) . According to the generally accepted view, MDR is defined as resistance to at least three antibiotics from the groups of β-lactam, carbapenem, aminoglycoside, and fluoroquinolone (3).
In some studies, mortality was reported to be around 70% in hospital-acquired pseudomonal pneumonia (4). This high rate of mortality was found to be associated with a high resistance pattern of P. aeruginosa (9).
The mean age of patients included in the study was high (65±12.4 years), and most of them were male (79.4%). It was observed that the number of patients with P. aeruginosa infection increased over the years (Table 1) . This increase was attributed to increasing patients and materials collected from these patients for evaluation.
The most commonly diagnosed diseases were chronic obstructive pulmonary disease (68.9%) and bronchiectasis (17.2%) ( Table 2 ). The finding of Pseudomonas infection in patients with bronchial carcinoma and tuberculosis was evaluated to be striking.
In this study, it was detected that P. aeruginosa strains were less resistant to AK (7.3%) and TOB (11.9%), and they were more resistant to FEP (26.7%) and CAZ (23.2%) ( Table 3) .
Carbapenems are among the broadest spectrum β-lactam antibiotics, and development of resistance to these antibiotics has been observed recently (10) . In this study, IMP resistance was found to be 21.8%. IMP resistance is reported to vary between 16.8% and 54% in studies conducted in Turkey (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) and between 7% and 37.4% in foreign studies (22, 27) . High resistance rates were detected in studies on intensive care patients ( Table 8) . As is seen in our study, the rate of IMP resistance is consistent with the studies conducted in Turkey but relatively higher than the studies conducted in other countries.
For AK from aminoglycosides, resistance develops more rarely than for other members of the group because AK is less affected by aminoglycoside-modifying enzymes (28) . In our study, the AK resistance rate was found to be 7.3%. The AK resistance rate is seen to vary between 4% and 38% in Turkish studies and between 3.3% and 38.8% in foreign studies (Table 8 ). According to these results, it can be said that AK resistance is low in Turkey and other countries at similar rates.
In our study, the CIP resistance rate was detected as 17.4%. This rate is similar to CIP resistance rates found in Turkey and other countries (Table 8) .
TOB resistance was found to be 11.9%. TOB resistance was detected between 4.5% and 58.4% in the studies performed in Turkey and other countries (Table 8) .
In this study, the PIP resistance rate was found to be 22.2%. It was demonstrated in Turkish and foreign studies that this resistance was at different rates varying from 10.8% to 58% (Table 8 ).
The resistance rate for FEP was detected to be 26.7%. Similar to our study, these rates are generally high in Turkey and other countries ( Table 8 ).
The CAZ resistance rate was 23.2%. Considering Table 8 , it can be said that CAZ resistance rates are very variable in Turkey and other countries.
Although an increase was observed in the rates of IMP, PIP, and P/T resistance over the years, no statistically significant difference was found among the resistance rates of IMP, TOB, PIP, P/T, and CAZ between the years of 2009 and 2013. The presence of a statistically significant difference in the resistance rates of CIP, AK, and FEP is a considerable finding. It is thought that this decrease was associated with the fact that the use of these antibiotics for lung infection due to Pseudomonas was low in our hospital.
As is seen in Table 5 , 53.5% of strains are susceptible to all antibiotics. It is striking that the number of strains resistant to three or more antibiotics is higher than the number of strains resistant to one or two antibiotics. In other words, when a resistant strain develops, the possibility for this strain to be resistant to three or more drugs is higher.
In this study, it was observed that resistance mosty developed to a single antibiotic group (19.2%). The rate of strains resistant to three or more antibiotics, namely MDR strains, was 12.1% (61 patients) (Table 6, 7). The rate of strains resistant to all antibiotic groups was 4% (resistant to all four groups). The rate of MDR strains was reported as 6.4% in the study of Al-Jasser and Elkhizzi (23) from Saudi Arabia, 5.7% by Raja and Singh (25) from Malaysia, 9.8% by Gailiene et al. (29) from Lithuania, and 3.3% by Yoshimura et al. (30) from Japan. It can be said that the MDR strain rate in our study is higher than that in other countries. Moreover, it was observed that the MDR strain rate, which was 18.2% in 2009, decreased to 12.4% in 2013 (Table 7) .
In our study, the rate of mortality that occurred during hospitalization in patients with isolated P. aeruginosa was found to be 6.7% (34 patients). This rate was reported as 51.1% in the study of Pinheiro et al. (27) and 25.2% in the study of Joo et al. (31) . The reason for lower mortality in our study than in other studies is that those studies were conducted among intensive care patients or patients with bacteremia.
CONCLUSION
The antibiotics to which P. aeruginosa strains are more susceptible are AK and TOB, and the antibiotics to which these strains are more resistant are FEP and CAZ. The resistance rates for CIP, AK, and FEP antibiotics decline over the years. Because the IMP resistance rates in Turkey were observed to increase gradually over the years and they were found to be higher than in other countries (although it was not statistically significant), it is suggested that the use of IMP in the treatment of P. aeruginosa infection should be reduced. The FEP resistance rates are generally high in our study and also in Turkey and other countries. However, it is pleasing that this resistance rate decreased over the years. While using empirical antibiotics in the treatment of P. aeruginosa, it should be kept in mind that the FEP, CAZ, and IMP resistance rates are high. Because approximately half of the strains display at least one antibiotic resistance, it is suggested that the use of at least two antibiotics in a treatment will be more Informed Consent: In this study, the microbiology database of isolated P. aeruginosa was retrospectively reviewed. So written/verbal informed consent was not obtained from patents who participated in this study.
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